Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced today that they have agreed to extend the agreement pertaining to the sales of telmisartan (Micardis® family) in Japan to March 31, 2020. The co-promotion agreement will run to March 31, 2018, with no change.
The Micardis® family includes “Micardis® Tablets 20 mg/40 mg/80 mg”, a long-acting angiotensin II receptor antagonist (generic name: telmisartan), “Micamlo® Combination Tablets AP/BP”, a combination drug of telmisartan and the long-acting calcium channel blocker amlodipine besylate, Micombi® Combination Tablets AP/BP, a combination drug of telmisartan and the thiazide diuretic hydrochlorothiazide, and Micatrio® Combination Tablets”, a combination drug of telmisartan, the long-acting calcium channel blocker amlodipine besylate and the thiazide diuretic hydrochlorazide.
The revision of the agreement will have no impact on financial results for the current fiscal year ending March 31, 2018.
